Shire Names Sushanta Mallick as VP, Global Development Lead for Ophthalmics

By

LEXINGTON, Mass—Shire has named Sushanta Mallick to its ophthalmics team as vice president and global development lead for clinical development, ophthalmics, according to a company announcement.

Sushanta, a former Alcon executive, has more than 20 years of experience in ophthalmology research and development, according to Shire.

“Although his primary area of development expertise has been in glaucoma, he has made significant contributions in the development of drugs in the wet AMD, dry eye and inherited retinal diseases,” the announcement noted. “With a strong scientific background and an MBA with marketing and international management focus, Sushanta provides a balanced perspective between the drug development and commercial needs.”

Sushanta most recently worked at Aerie Pharmaceuticals as VP, clinical research/glaucoma, and prior to that he was VP of research and development at QLT Inc. in Vancouver, where he led the R&D activities and directed the development of oral synthetic retinoid as an orphan drug in inherited retinal diseases.

Earlier in his career, Sushanta spent 19 years with Alcon, where he held a number of positions of increasing responsibility. He also has made product presentations to ophthalmologists, health care providers and company sales teams in the U.S., Europe, Asia and South America during his career.